



# Hydrogen Sulfide Mediating both Excitatory and Inhibitory Effects in a Rat Model of Meningeal Nociception and Headache Generation

Christiane Teicher, Roberto De Col and Karl Messlinger\*

Institute of Physiology and Pathophysiology, University of Erlangen-Nürnberg, Erlangen, Germany

**Background/purpose:** Hydrogen sulfide ( $H_2S$ ) is a neuromodulator acting through nitroxyl (HNO) when it reacts with nitric oxide (NO). HNO activates transient receptor potential channels of the ankyrin type 1 (TRPA1) causing release of calcitonin generelated peptide from primary afferents. Activation of meningeal nociceptors projecting to the human spinal trigeminal nucleus (STN) may lead to headaches. In a rat model of meningeal nociception, the activity of spinal trigeminal neurons was used as read-out for the interaction between  $H_2S$  and NO.

### **OPEN ACCESS**

### Edited by:

László Vécsei, University of Szeged, Hungary

#### Reviewed by: Marcelo M. Valença,

Federal University of Pernambuco, Brazil Dan Levy, Harvard Medical School, United States

\*Correspondence: Karl Messlinger karl.messlinger@fau.de

#### Specialty section:

This article was submitted to Headache Medicine and Facial Pain, a section of the journal Frontiers in Neurology

Received: 15 March 2017 Accepted: 27 June 2017 Published: 14 July 2017

### Citation:

Teicher C, De Col R and Messlinger K (2017) Hydrogen Sulfide Mediating both Excitatory and Inhibitory Effects in a Rat Model of Meningeal Nociception and Headache Generation. Front. Neurol. 8:336. doi: 10.3389/fneur.2017.00336 **Methods:** In anesthetized rats extracellular recordings from single neurons in the STN were made. Sodium sulfide (Na<sub>2</sub>S) producing  $H_2S$  in the tissue and the NO donor diethylamine-NONOate (DEA-NONOate) were infused intravenously.  $H_2S$  was also locally applied onto the exposed cranial dura mater or the medulla. Endogenous production of  $H_2S$  was inhibited by oxamic acid, and NO production was inhibited by nitro-L-arginine methyl ester hydrochloride (L-NAME) to manipulate endogenous HNO formation.

**Key results:** Systemic administration of Na<sub>2</sub>S was followed either by increased ongoing activity (in 73%) or decreased activity (in 27% of units). Topical application of Na<sub>2</sub>S onto the cranial dura mater caused a short-lasting activation followed by a long-lasting decrease in activity in the majority of units (70%). Systemic administration of DEA-NONOate increased neuronal activity, subsequent infusion of Na<sub>2</sub>S added to this effect, whereas DEA-NONOate did not augment the activity after Na<sub>2</sub>S. The stimulating effect of DEA-NONOate was inhibited by oxamic acid in 75% of units, and  $\lfloor$ -NAME following Na<sub>2</sub>S administration returned the activity to baseline.

**Conclusion:** Individual spinal trigeminal neurons may be activated or (less frequently) inhibited by the TRPA1 agonist HNO, presumably formed by  $H_2S$  and NO in the STN, whereby endogenous  $H_2S$  production seems to be rate-limiting. Activation of meningeal afferents by HNO may induce decreased spinal trigeminal activity, consistent with the elevation of the electrical threshold caused by TRPA1 activation in afferent fibers. Thus, the effects of  $H_2S$ –NO–TRPA1 signaling depend on the site of action and the type of central neurons. The role of  $H_2S$ –NO–TRPA1 in headache generation seems to be ambiguous.

Keywords: nitroxyl, hydrogen sulfide, nitric oxide, trigeminal nucleus caudalis, meningeal nociception, extracellular recording, migraine, headache

# INTRODUCTION

Hydrogen sulfide (H<sub>2</sub>S) is a toxic gas released from natural and artificial sources (1), but at very low concentrations it acts within the body as a signal molecule in the cardiovascular and the central nervous system (2, 3). Endogenous H<sub>2</sub>S is cleaved from cysteine by pyridoxal-5'-phosphate-dependent enzymes, particularly cystathionine  $\beta$ -synthase (CBS) and cystathionine  $\gamma$ -lyase (4–8). In addition to its cardiovascular and central functions, H<sub>2</sub>S exerts various biological effects like insulin secretion from rat pancreatic B-cells (9), facilitation of carotid sinus baroreceptor activity (10), and relaxation of human airway smooth muscle cells (11) through activation of KATP channels. H2S may inhibit Ca2+-activated K+ channels and the Na+-K+-ATPase, thus contributing directly to depolarization of pulmonary epithelial cells (12). An overproduction of H<sub>2</sub>S may be implicated in severe diseases like sepsis and colorectal cancer, where it seems to be a cell protective factor, while in other diseases H<sub>2</sub>S levels are reduced (13). H<sub>2</sub>S-mediated signaling pathways are not only mediated by the intact compound but also by its oxidized forms, polysulfides.

Because of its neuromodulating effects in the nervous system, H<sub>2</sub>S has been regarded as the third "gasotransmitter" besides nitric oxide (NO) and carbon monoxide (14). H<sub>2</sub>S and NO react preferably to form nitroxyl (HNO), the one-electron-reduced sibling of NO, which has been shown to be a strong activator of transient receptor potential (TRP) channels of the ankyrin type 1 (TRPA1) (15). TRPA1 channels are expressed in a subset of nociceptive primary spinal and trigeminal afferents, mainly co-existent with TRP channels of the vanilloid type 1 (TRPV1) (16-18). Opening of TRPA1 and TRPV1 receptor channels in primary afferent neurons at normal membrane potentials allows inward currents of Na<sup>+</sup> and Ca<sup>2+</sup>, which depolarize the cell membrane and lead to the exocytosis of neuropeptides like substance P and calcitonin gene-related peptide (CGRP) in neurons storing these peptides (19, 20). This signaling cascade has recently been demonstrated in a variety of in vivo and in vitro experiments in our laboratory to cause CGRP release from trigeminal afferent fibers in the rat dura mater followed by increased meningeal blood flow (21).

Similar signaling mechanisms as in peripheral tissues have frequently been found in the spinal and medullary dorsal horn. Indeed, there is histological evidence for H<sub>2</sub>S–NO–CGRP signaling in the spinal trigeminal nucleus (STN) (21), where the central trigeminal terminals project to second order neurons. We hypothesized therefore that the gasotransmitters H<sub>2</sub>S and NO are also involved in modulating the activity of these central neurons. The second order neurons in the STN receiving primary afferent input from the cranial meninges (22, 23) may have a pivot function in central nociceptive processing that causes the sensation of headaches. A putative role of TRPA1 receptor channels in the pathogenesis of headaches has particularly been discussed after recognizing that TRPA1 agonists like umbellulone, a product of the "headache tree," may initiate headache and migraine attacks (24). Thus, assuming that the endogenous production of  $H_2S$  and NO forming HNO (25, 26) contributes to the control of neuronal activity by activating TRPA1 receptors and CGRP release in the STN (15), we tried to manipulate this signaling cascade by application of an  $H_2S$  and an NO donor and inhibiting endogenous  $H_2S$  or NO production using the spinal trigeminal activity as a read-out in an established animal model of meningeal nociception. The results indicate that individual spinal trigeminal neurons may be activated or inhibited by  $H_2S$ –NO–CGRP signaling, possibly depending on the site of action and the type of central neurons involved.

# MATERIALS AND METHODS

## **Anesthesia and General Preparation**

The experiments were performed on adult male Wistar rats with body weights of 250–350 g, bred and housed in the animal facility of our Institute. All experiments were done in accordance with the ethical guidelines of the International Association for the Study of Pain and in compliance with the guidelines for the welfare of experimental animals of the Federal Republic of Germany and the European Commission (Directive 2010/63/EU). The experimental protocol was reviewed by an ethics committee and approved by the District Government of Unterfranken.

For anesthesia, the animals were placed into a closed box, which was filled with an air-oxygen-mixture and isoflurane (Forane® Vapor 19.3, Drägewerk AG, Lübeck, Germany) at increasing concentrations up to 4%; then isoflurane at 2.5% was applied through a mask for surgical procedures. The right femoral artery was catheterized to monitor arterial blood pressure, which ranged between 70 and 120 mmHg. The catheter system contained heparin sodium 5000 (Ratiopharm GmbH, Ulm, Germany) in a 1:5,000 solution with sodium chloride 0.9% (B. Braun Melsungen AG, Melsungen, Germany). Furthermore, the right femoral vein was cannulated to allow infusion of solutions and drugs. To guarantee safe machine-assisted ventilation with oxygen-enriched room air over several hours, the rats were intubated with an intravenous cannula (Vasuflo®-T G14, Dispomed Witt, Germany). Atropine sulfate (B. Braun Melsungen AG, Melsungen, Germany, 0.5 mg/ml 1:10 with sodium chloride 0.9%) was injected subcutaneously to prevent salivation and muscle spasms.

Physiological monitoring of vital parameters (mean blood pressure, expiratory  $CO_2$  levels, respiratory rate, and body temperature) was ensured throughout the experiment. To maintain a constant body temperature of 37.9–38.2°C, each rat was placed on a heating plate connected to a feedback-controlled homeothermic system (TKM 0902, FMI GmbH, Seeheim Ober-Beerbach, Germany). During the experiment, an isoflurane concentration of 2% was adequate to maintain a constant depth of anesthesia, deactivated motor reflexes to noxious pinch stimuli of the hind paw and a constant blood pressure. The end-expiratory  $CO_2$  was monitored by a sensor (HeyerArtema MM 200, Bad Ems, Germany) and kept at 2.5–3.0% to suppress any spontaneous

Abbreviations: CBS, cystathionine  $\beta$ -synthase; CGRP, calcitonin gene-related peptide; CO, carbon monoxide; CSE, cystathionine  $\gamma$ -lyase; DEA-NONOate, diethylamine-NONOate; H<sub>2</sub>S, hydrogen sulfide; HNO, nitroxyl; L-NAME, nitro-L-arginine methyl ester hydrochloride; Na<sub>2</sub>S, sodium sulfide; NO, nitric oxide; NOS, nitric oxide synthase; SIF, synthetic interstitial fluid; STN, spinal trigeminal nucleus; TRPA1, transient receptor potential channel of the ankyrin type 1; TRPV1, transient receptor potential channels of the vanilloid type 1.

breathing. In case of a ventilation resistance exceeding 10 mmHg, saliva was removed with a blunt plastic cannula through the tracheal tube.

## **Head Surgery**

The rat's head was fixed in a stereotactic frame and held by ear bars and a snout clamp. To avoid activation of nociceptors in the auditory canal, local anesthetic ointment containing lidocaine (Posterisan<sup>®</sup> akut, Dr. Kade Pharma, Konstanz, Germany) was used. The eyes were covered with dexpanthenol ointment (Bepanthen®, Bayer Vital GmbH, Leverkusen, Germany) to prevent dehydration of the cornea. A median incision was made along the midline of the scalp and the skin of the neck. A cranial window of about 10 mm  $\times$  7 mm was carefully cut into the right parietal bone using a dental drill (KaVo EWL, max. 25,000/min, KaVo Dental GmbH, Biberach, Germany) under saline rinsing. The exposed dura was covered with isotonic saline throughout the experiment. Then, the medulla oblongata containing the caudal part of the STN was exposed. The neck muscles and the dorsal atlanto-occipital ligament with the underlying dura mater were incised and pulled apart to expose the cisterna cerebellomedullaris (c. magna). In some experiments, parts of the atlas vertebra were excised to gain access to the upper cervical segments.

# Stimulation and Data Recording

For extracellular recording from single neurons in the STN, custom-made carbon fiber glass microelectrodes with an impedance of about 1 M $\Omega$  were slowly advanced at 2.5  $\mu$ m steps through the ipsilateral medullary brainstem driven by a nanostepper (SMS87 TC Elektronik, Würzburg, Germany) (Figure 1A). Neurons in the subnucleus caudalis of the STN with meningeal nociceptive input were detected by their spiking evoked by touching the parietal dura with von Frey filaments (2.9-11.8 Nm). Besides their responses to mechanical stimulation of the dura, the recorded neurons matched the criteria of being spontaneously active with a minimal steady frequency of one per second and action potentials with amplitudes of at least 20 mV. Prior to recording, a muscle relaxant (gallamine triethiodide, Sigma G 8134, Sigma-Aldrich Chemie GmbH, Germany, 50 mg/ml sodium chloride 0.9%) was i.v. infused (initially 0.3 ml, then 0.2 ml every 2 h) to avoid muscular contractions to electrical stimuli.

Convergent input from extracranial tissues was mapped by probing the ipsilateral cornea, temporal muscle, periosteum, and facial skin (V1, 2, 3) with von Frey filaments and a fine blunt glass rod. A custom-made mechanostimulator was placed on the meningeal receptive field to deliver impulses of 1-s duration every minute with an optimized force (range 15–25 mN, about three times the von Frey filaments threshold) eliciting a cluster of 5–20 action potentials. The data were recorded with the computer software Spike2 6.08 (Cambridge Electronic Design, Cambridge, UK) and saved for later offline analysis (**Figure 1B**). After finishing the recordings, electrical single shock stimuli were applied with bipolar electrodes to the exposed parietal dura to determine the electrical threshold just activating the neuron. In addition, responses to topically applied capsaicin  $(10^{-6} \text{ M})$  were assessed.



**FIGURE 1** | Experimental setup and data recording. **(A)** Extracellular recording (Rec) of neuronal activity in the spinal trigeminal nucleus (STN). Meningeal afferents were stimulated by repetitive mechanical stimuli applied to the exposed parietal dura mater in a cranial window around the middle meningeal arteria (MMA). SSS, superior sagittal sinus; TG, trigeminal ganglion. **(B)** Original recording of neuronal activity. Repetitive mechanical stimuli elicit clusters of action potentials in addition to the ongoing activity. The counted spikes in the offline analysis are presented on top. **(C)** Spike histogram of ongoing neuronal activity and changes after systemic administration of vehicle, sodium sulfide (Na<sub>2</sub>S), and nitro-L-arginine methyl ester hydrochloride (L-NAME) in a typical experiment.

At the end of each experiment, the coordinates of the electrode in relation to the obex as well as the depth of the recording site were measured. The experiments were terminated by i.v. injection of a lethal dose of 6% thiopental (Trapanal<sup>®</sup>, Nycomed Deutschland GmbH, Konstanz, Germany).

#### H<sub>2</sub>S in Trigeminal Nociception

### Chemicals

A stock solution of 100 mM sodium sulfide (Na<sub>2</sub>S) (Department of Chemistry and Pharmacy, FAU Erlangen) was diluted to 300 µM with synthetic interstitial fluid (SIF) for topical application or to 900 µM with saline for intravenous infusion. The CGRP receptor antagonist Olcegepant (BIBN4096BS, Boehringer Ingelheim Pharma KG, Germany) was dissolved in acidic pH at 1 mg/ml and then titrated to neutral values. The nitric oxide synthase (NOS) inhibitor nitro-L-arginine methyl ester hydrochloride (L-NAME) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) was dissolved in saline for intravenous infusion at a dose of 10 mg/kg. The NO donor diethylamine-NONOate (DEA-NONOate) (Merck Millipore, Schwalbach, Germany) was dissolved in 10 mM NaOH and diluted in saline immediately before intravenous infusion at a dose of 2.5 µg/kg. An inhibitor of H<sub>2</sub>S synthesis, oxamic acid (aminooxyacetic acid) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany), was dissolved in saline for intravenous infusion (3 mg/kg).

## **Experimental Protocols**

Each experiment started with a control stimulation period (baseline recording) followed by intravenous infusion of saline or topical application of SIF as a vehicle. After the test stimulation period, a post-control period was added. Each recording period following application of any substance lasted 20 min, which is long enough to assure changes in neuronal activity caused by experimental manipulations but allows also a sequence of several recording periods within a reasonable time.

In the first group of 19 animals,  $Na_2S$  was topically (50 µl, 300 µM) applied to the exposed dura and/or to the spinal medulla and/or slowly injected intravenously (i.v., 0.3 ml, 900 µM) over 2 min in arbitrary order. In nine experiments  $Na_2S$  was administered to the dura and/or the medulla and injected i.v., in eight experiments either to the dura or the medulla or i.v. Subsequently, L-NAME (0.5 ml, 10 mg/kg) was added intravenously (**Figure 1C**). Finally, in five experiments Olcegepant was i.v. injected 20 min after L-NAME at a dose of 1 mg/kg to check if activated CGRP receptors were still present contributing to the ongoing activity.

In the second test group, 14 neurons (in 14 animals) were infused by DEA-NONOate (0.2 ml, 2.5  $\mu$ g/kg) followed by oxamic acid (0.2 ml, 3 mg/kg) in eight cases. The infusion was held at a low constant rate of 1.2 ml/h to avoid changes in systemic blood pressure possibly induced by these vasoactive substances. The activity was then recorded for other 30 min.

In the third test group of six animals, the effect of i.v. administration of  $Na_2S$  (0.25 ml) before and after DEA-NONOate (0.2 ml) was tested. Each substance was infused over a period of 5–6 min (2.4 ml/h), and the recording was continued for 20 min.

### **Data Analysis**

The neuronal activity of recorded neurons was analyzed with Spike2 6.08 (Cambridge Electronic Design, Cambridge, UK) after it had been cleaned from artifacts using the touch-evoked responses as templates. The number of spikes was counted and listed at intervals of minutes (partly also seconds) with Excel software 2013 (Microsoft Corporation, USA) to determine mean values of activity and SEM (mean  $\pm$  SEM). For calculating the

ongoing activity, the mechanically evoked activity was subtracted. The mechanically evoked activity is the activity during the 1-s mechanostimulation interval diminished by the mean ongoing activity within 1 s before and 1 s after stimulation. For generating diagrams, the ongoing and the mechanically evoked activity was normalized to the mean baseline activity recorded during vehicle.

For statistical analysis Statistica 7.0 software (StatSoft, Tulsa, OK, USA) was used. The neuronal activity of each individual unit counted at 1-min intervals was analyzed with one-way ANOVA followed by Fisher's least significance difference (LSD) *post hoc*-test to compare the variance in activity before and after drug administration. The activity of units within each particular group was then evaluated by ANOVA with repeated measurements, also followed by Fisher's LSD *post hoc*-test. Furthermore, the Wilcoxon matched pairs test (for n < 10) or the Student's *t*-test ( $n \ge 10$ ) was performed for comparing the neuronal activity before and after administration of drugs. Differences were regarded significant at p < 0.05.

The diagrams were created with Origin 7 software (OriginLab Corporation, USA) and edited by CorelDRAW Graphics Suite X8 software (Corel Corporation, Canada).

# RESULTS

## **General Properties of Neurons**

Recordings were made from 32 neurons in the STN of 32 rats. The neurons were characterized by their afferent input from the exposed ipsilateral parietal dura mater; the receptive fields were mostly located close to the middle meningeal artery. Additionally, convergent input from the ophthalmic, maxillary, and mandibular areas of the facial fur, the temporal or neck muscles, and the periosteum around the cranial window was determined. All neurons but one responded to touch or light pressure applied to facial receptive fields in addition to their meningeal input and were therefore classified as wide dynamic range neurons.

The recording sites were located 1.1/1.8/3.0 mm (min/mean/max) caudal to the obex, 0.6/1.2/1.9 mm ipsilateral from the midline and at depths of 98/748/1,327 µm below the dorsal surface of the medulla. The ongoing activity of the recorded units during the control period varied between 97 and 2,038 (mean 497 ± 91) spikes per minute. Nearly all units located in superficial layers of the trigeminal nucleus ( $\leq$ 500 µm) had low spontaneous activity (<400/min), but in the whole sample the depth of recording sites and the unit's spontaneous activity showed no significant correlation.

The mechanical threshold determined by graded von Frey filaments ranged between 0.98 and 6.9 mN (mean  $4.1 \pm 0.3$  mN). The electrical threshold identified by electrical square pulses (duration 1 ms) applied to the dural receptive field at the end of the experiments ranged from 0.02 to 8 mA (mean  $2.33 \pm 0.64$  mA). The nerve fibers responded with latencies between 5 and 25 ms (mean  $16 \pm 1.9$  ms) to single electrical pulses slightly above threshold. Assuming an average distance of 25 mm from the stimulation area on the dura to the recording site in the brainstem, the afferent fibers activating the units could be classified as A $\delta$ -fibers (>2 m/s) or C-fibers (<2 m/s) at a proportion of about 40/60%. Twelve units were tested with capsaicin topically administered to the exposed dura mater as a chemical stimulus for nociceptors. All tested units responded immediately with clusters of five to twenty action potentials.

## Neuronal Responses to Na<sub>2</sub>S/H<sub>2</sub>S

Hydrogen sulfide has been defined as a neuromodulator in nociceptive processing (27). The first series of experiments was made to examine if systemic or local application of H<sub>2</sub>S modulates the activity of spinal trigeminal neurons processing meningeal afferent information. We hypothesized that H<sub>2</sub>S binds to endogenous NO to form HNO that may activate TRPA1 receptor channels of primary meningeal afferents resulting in an increased spinal trigeminal activity.

### Vehicle Control

In seven units the spontaneous baseline activity was recorded for 20 min, and the variance in activity in each minute was compared to the variance in activity within 20 min after i.v. injection of saline as a vehicle control. ANOVA analysis at 1-min intervals yielded four units without changes, two units with increased activity after saline, and one unit with decreased activity. In another sample of 10 units, the activity was recorded 20 min before and after topical application of vehicle (saline) to the exposed dura mater. In eight units, there was no change, and in two units the activity decreased after vehicle. In the two samples of units, there was no significant change in activity over the control time.

### Systemic Administration of Na<sub>2</sub>S

In 15 units, ongoing and mechanically evoked activity was recorded 20 min before and after i.v. infusion of Na<sub>2</sub>S. Although an increase in ongoing activity after Na<sub>2</sub>S infusion was apparent, it was statistically not significant in the whole sample of experiments. The analysis of each single unit with one-way ANOVA at 1-min intervals revealed 11 units with higher activity after Na<sub>2</sub>S, while 4 units showed a significant decrease in activity after Na<sub>2</sub>S compared to baseline/vehicle. In the group of the 11 neurons, the activity analyzed within 10-min intervals was significantly higher after Na<sub>2</sub>S compared with the intervals after baseline and vehicle [ANOVA with repeated measurements, F(4, 40) = 5.651, p < 0.01; followed by LSD test, p < 0.01-0.05] (Figures 2A,B).

The mechanically evoked activity did not show any significant change in activity, regardless if all units or the units with increased spontaneous activity after Na<sub>2</sub>S administration were analyzed.

### Dural Administration of Na<sub>2</sub>S

Ten units were recorded during topical application of Na<sub>2</sub>S onto the dura mater. The activity of the whole cohort analyzed at intervals of 1 and 10 min tended to decrease without statistically significant variation. The analysis of individual experiments by one-way ANOVA showed that the ongoing activity in 7 of 10 units decreased after Na<sub>2</sub>S, in 2 units there was no change, and in one the activity was increasing. In the group of seven units, the decrease in neuronal activity was significant compared to the baseline/vehicle activity analyzed at intervals of 10 min [ANOVA with repeated measurements, *F*(5, 30) = 2.632, *p* < 0.05; LSD test, *p* < 0.05] (**Figure 3A**).

The mechanically evoked activity did not significantly change after Na<sub>2</sub>S application.





In primary meningeal afferent recordings *in vitro*, we observed a short-lasting transient excitation after topical application of the HNO donor Angeli's salt (unpublished experiments). Because in some of the present experiments a short-lasting activation immediately following Na<sub>2</sub>S application onto the dura mater was obvious, we evaluated the activity of the whole sample at intervals of 2 s around the application, resulting in a significant increase in activity for 4 s after Na<sub>2</sub>S application [ANOVA with repeated measurements, F(3, 24) = 3.339, p < 0.05; LSD test p < 0.05] (**Figure 3B**). The application of vehicle was not followed by any comparable change in activity.

### Medullary Administration of Na<sub>2</sub>S

Responses to topical application of Na<sub>2</sub>S/H<sub>2</sub>S onto the spinal medulla were examined in 11 units. The whole group did not show any significant change in activity. Analyzing individual units, an



(B) normalized to the respective vehicle intervals, and changes after dural administration of sodium sulfide (Na<sub>2</sub>S). (A) The whole sample of 10 units showed a tendency of decreased activity without significant change following local application of Na<sub>2</sub>S onto the dura mater. The analysis of each single unit (one-way ANOVA at minute intervals) resulted in a significant decrease in neuronal activity in seven units. In this group, the decrease in activity was significant compared to baseline/vehicle (\*) intervals (ANOVA with repeated measures). Three units were not inhibited by topical Na<sub>2</sub>S. (B) Higher resolution at 2-s intervals showed a short-lasting significant increase in activity between one interval before and the first two intervals after Na<sub>2</sub>S application (\*) but not after vehicle.

increased activity was visible in six units. The activity of these six units increased significantly between minute 5 and 7 after administration of Na<sub>2</sub>S compared to the 10 min before drug application [ANOVA with repeated measurements, F(19, 95) = 1.935, p < 0.05; followed by LSD test, p < 0.05] (**Figures 4A,B**). There was no change in activity following vehicle administration.

The mechanically evoked activity did not significantly change after Na<sub>2</sub>S application.

# Neuronal Interaction between Na<sub>2</sub>S and DEA-NONOate

Hydrogen sulfide interacting with NO may be more effective than  $H_2S$  alone, which has recently been concluded from measurements



**FIGURE 4** Activity of units displayed at 10-min (A) or 1-min intervals **(B)** normalized to the respective vehicle intervals, and changes after medullary administration of sodium sulfide (Na<sub>2</sub>S). (A) The whole sample of 11 units showed no significant change in activity after local administration of Na<sub>2</sub>S onto the spinal medulla. When each single unit was evaluated separately (one-way ANOVA at minute intervals), the neuronal activity of six units was increasing after Na<sub>2</sub>S but not after vehicle administration. **(B)** Higher resolution revealed increased activity (\*) in the group of activated units in minutes 5–7 after starting Na<sub>2</sub>S administration compared to the 10-min interval before Na<sub>2</sub>S infusion (ANOVA with repeated measures).

of CGRP release from medullary slices (28). Therefore, in a variety of experiments we combined  $Na_2S$  and DEA-NONOate and inhibited the endogenous production of  $H_2S$  by oxamic acid or the NO production by L-NAME, which has previously been shown to lower the activity of spinal trigeminal neurons with meningeal afferent input (29). The CGRP receptor inhibitor, BIBN4096BS (Olcegepant), was eventually applied.

### Vehicle Control

In 21 units, the spontaneous activity was recorded for 20 min and the variance in activity between the minutes compared to the variance in activity within 20 min after infusion of vehicle (saline). In five units, there was no change, in eight units, the activity increased, and in eight others it decreased. The whole group showed no significant change in activity.

### Systemic Administration of DEA-NONOate

The NO donor DEA-NONOate was systemically administered in 14 experiments. The neuronal activity was recorded over 40 min



(10-min infusion period and subsequently 30 min) and evaluated at 20-min intervals. During infusion of DEA-NONOate an increased activity was apparent followed by a second phase of increased neuronal activity over the next 30 min [two-way ANOVA with repeated measurements, DEA-NONOate compared to vehicle, F(1, 13) = 21.646, p < 0.001; LSD test, p < 0.001–0.01] (Figure 5).

The mechanically evoked activity did not significantly change after DEA-NONOate administration.

# Systemic Administration of Na<sub>2</sub>S Combined with DEA-NONOate

In six units, Na<sub>2</sub>S and DEA-NONOate were administered intravenously at intervals of 20 min followed by a second Na<sub>2</sub>S administration. The neuronal activity tended to increase after the first Na<sub>2</sub>S infusion and after DEA-NONOate; after the second Na<sub>2</sub>S infusion there was a rapid increase in activity, particularly during minute 4–9 after start of the infusion [ANOVA with repeated measurements, F(24, 96) = 1.6813, p < 0.05; LSD test, p < 0.05] (**Figure 6**). Looking at the six individual units, there was a significant change in activity between Na<sub>2</sub>S before and after DEA-NONOate in each case: it was increasing in four (one-way ANOVA, p < 0.01; LSD test, p < 0.001) and decreasing in two units (one-way ANOVA, p < 0.01; LSD test, p < 0.001).

There was no significant change in the mechanically evoked activity.

# Inhibition of Endogenous H<sub>2</sub>S and NO Synthesis

# Systemic Administration of Oxamic Acid following DEA-NONOate

In eight experiments, the administered DEA-NONOate was followed by oxamic acid inhibiting endogenous  $H_2S$  synthesis. Comparing 10 min before and after application of oxamic acid, the Wilcoxon matched pairs test detected a just significant decrease



vehicle intervals and changes after consecutive systemic administration of sodium sulfide (Na<sub>2</sub>S), diethylamine-NONOate (DEA-NONOate) and a second Na<sub>2</sub>S stimulus. The six units showed no significant change in activity after the first Na<sub>2</sub>S and the DEA-NONOate infusion but a significant increase (\*) in minutes 4–9 after starting the second Na<sub>2</sub>S infusion compared to the 10-min intervals before the respective drug application (ANOVA with repeated measures).

in activity (p < 0.05) (**Figure 5**), which was due to the majority of six units, while in two units the activity increased further after oxamic acid (one-way ANOVA of individual units, p < 0.001).

The mechanically evoked activity did not show significant changes.

### L-NAME following Systemic Administration of Na<sub>2</sub>S

In seven experiments, the NO synthase inhibitor, L-NAME, was i.v. applied 20 min after Na<sub>2</sub>S administration to figure out if endogenous NO production is required for the long-lasting increase in activity following Na<sub>2</sub>S administration in the majority of units. Since the activity seemed to fluctuate within short periods after the administration of L-NAME, it was analyzed with higher resolution at 2-min intervals. The activity tended to increase after Na<sub>2</sub>S administration. From 6 min after L-NAME it decreased significantly compared to minute 2–14 after Na<sub>2</sub>S application and was finally below the level of baseline and vehicle [ANOVA with repeated measurements, *F*(69, 414) = 1.382, *p* < 0.05; LSD test, *p* < 0.05] (**Figure 7**). Finally, the CGRP receptor inhibitor BIBN4096BS (olcegepant) added in five units did not lead to a further decrease in activity.

An increase in blood pressure between 10 and 50 mmHg (mean 28 mmHg) occurred 60–290 s after L-NAME administration.

The mechanically evoked activity did not significantly change after L-NAME administration.

# DISCUSSION

### Neuronal Responses to Na<sub>2</sub>S/H<sub>2</sub>S

Spinal trigeminal neurons processing nociceptive information from the dura mater encephali seem to respond differentially to



Na<sub>2</sub>S/H<sub>2</sub>S. Systemic application of Na<sub>2</sub>S caused activation in the majority of units (73%), whereas in a minor proportion the activity slowly decreased within 10–20 min after infusion of Na<sub>2</sub>S. The mechanically evoked activity remained unchanged. After topical administration of Na<sub>2</sub>S onto the spinal medulla these two different groups were also visible, though with minor significance. In contrast, topical administration of Na<sub>2</sub>S onto the cranial dura mater caused a very short-lasting activation followed by a slow and long-lasting decrease in activity in most of the units. These different behaviors were not correlated with any other criteria characterizing the units like basal spontaneous activity or convergent afferent input from facial areas.

### Systemic Administration of Na<sub>2</sub>S

The seeming discrepancy of both activated and inhibited units warrants a discussion about the neuronal effects of  $H_2S$ , which may vary depending on several factors.  $H_2S$  is known as a potent activator of TRPA1 receptor channels (30) subserving pro-nociceptive actions of  $H_2S$  in somatic tissues (27). TRPA1 activation is involved in sensory transduction in nociceptors, particularly during inflammation and oxidative stress (31). TRPA1 has been found functionally expressed primarily in the isolectin  $B_4$ -positive, CGRP-negative subpopulation of small lumbar DRG neurons (32). Therefore, TRPA1 activated by HNO may initiate different signaling pathways resulting in the peripheral and central release of CGRP in a smaller proportion of primary afferents.

Besides its activating effect on TRPA1 receptor channels,  $H_2S$  may be involved in multiple signaling pathways in the peripheral and central nervous system by targeting ion channels like T-type and L-type calcium channels, ATP-sensitive K<sup>+</sup> (K<sub>ATP</sub>) channels and *N*-methyl-D-aspartate channels, which modulate nociceptive processes [reviewed in Ref. (33)].  $H_2S$  may also activate Ca<sup>2+</sup>-dependent K<sup>+</sup> channels (BKCa), the delayed rectifier

 $K^+$  current (I<sub>K</sub>) as well as one type of sodium channel (Na<sub>v</sub>1.5); and finally, TRPV1 and chloride channels are also suggested to be modulated by  $H_2S$  (34). Due to its multiple actions, it is not surprising that H<sub>2</sub>S has been reported to act ambiguously, being beneficial or harmful depending on its concentration and cellular location (35). H<sub>2</sub>S at micromolar concentrations has cytoprotective and antioxidant effects, whereas H<sub>2</sub>S exposure in the millimolar range potentiates redox stress and is cytotoxic [reviewed in Ref. (34)]. The effective concentration of H<sub>2</sub>S in the organisms depends on several factors like pH, temperature, and oxygen, which may lead to opposite effects. In alkaline solutions, sulfide exists predominantly as highly reactive HS<sup>-</sup> anion, and low temperatures lead to a higher percentage of H<sub>2</sub>S gas (36). H<sub>2</sub>S production is particularly increased in hypoxic conditions (37). Also, systemic cardiovascular effects of H<sub>2</sub>S may interact differentially with the neuronal responses. Infusions of the H<sub>2</sub>S donors, Na2S and NaHS, in rats decreased systemic arterial pressure and heart rate dose-dependently, which could not sufficiently be explained by distinct peripheral or central signaling mechanisms (38).

It is likely that the cardiovascular effects as well as a major part of H<sub>2</sub>S effects in the central nervous system including the spinal trigeminal system is attributed to the synthesis of HNO/NO<sup>-</sup> in the presence of NO and H<sub>2</sub>S, leading to CGRP release from sensory neurons through TRPA1 activation (15). Thus, it is tempting to assume that the individual endogenous production of NO close to the recorded neuron may be another factor influencing H<sub>2</sub>S effects. Moreover, it is likely that not all spinal neurons are controlled by NO, and finally, H<sub>2</sub>S itself or the generated HNO might have an activating effect on inhibitory neurons, which could inverse the activation and eventually lead to an inhibition of the recorded unit. We propose this hypothesis based on preliminary findings of our group (unpublished): Patch clamp recordings in medullary slices revealed that Na<sub>2</sub>S has predominantly depolarizing effects on neurons in superficial laminae of the STN, but in some neurons hyperpolarizing effects occurred. Furthermore, in a previous study it was hypothesized that neuronal NOS and inducible NOS (but not endothelial NOS) were irreversibly inhibited by H<sub>2</sub>S/NO at modest concentrations of H<sub>2</sub>S in a reaction that may allow feedback inhibition of NO production under conditions of excessive NO/H<sub>2</sub>S formation (39).

We cannot definitely exclude that the experimental test setup has influenced the results, since in the majority of experiments i.v. administration was performed after topical application of Na<sub>2</sub>S onto the dura mater and/or the medulla oblongata. However, there was not any significant correlation between the pretreatment and an inhibiting H<sub>2</sub>S effect. We assume that the time intervals between local and systemic application of Na<sub>2</sub>S were long enough to exclude such an interaction.

The lacking change in mechanically evoked activity may indicate an exclusively central effect of  $Na_2S/H_2S$  on the neurons we have recorded from. Another possibility is that the predominantly activating central effect of  $H_2S$  upon systemic administration of  $Na_2S$  was compensated by the predominantly inhibitory effect on primary meningeal afferents as discussed below.

### H<sub>2</sub>S in Trigeminal Nociception

### Dural Administration of Na<sub>2</sub>S

After topical application of Na<sub>2</sub>S onto the dura mater, the neuronal activity unexpectedly decreased in the majority (70%) of units within the next 20 min. Analyzing the activity at time intervals of seconds, it turned out that there was a very short-lasting activation (maximally 12 s after application) in the majority of units. This fits to previous recordings from meningeal afferents in vitro, where a short-lasting activation under superfusion with the HNO donor Angeli's salt was followed by a long-lasting inhibition of primary afferent activity (unpublished data of our group). However, this short activation of primary afferents is probably not responsible for the delayed activation seen in the majority of spinal trigeminal units after systemic administration of Na<sub>2</sub>S, because there was no correlation between these effects. In recent recordings in the abovementioned in vitro set meningeal primary afferents showed increased thresholds when they were activated by TRPA1 receptor agonists like acrolein or mustard oil (40). Thus, activation of TRPA1 receptors may be the reason why the stimulating effect of H<sub>2</sub>S can eventually decrease the activity of spinal trigeminal neurons. We know from previous studies that the activity of these neurons is partly dependent on an ongoing afferent input, since local anesthesia of trigeminal afferents leads to a significant decrease in activity in these neurons (41).

### Medullary Administration of Na<sub>2</sub>S

The neuronal response to  $Na_2S$ , administered onto the medulla oblongata, did not lead to a significant effect in the whole sample of recorded units, though in about half of the units the activity increased. This may imply that the neuronal response to  $H_2S$  in the medulla is regulated by further—so far unknown—factors, but it seems more likely that  $Na_2S$  did not reach the cellular environment of the STN at an adequate concentration. Since cerebrospinal fluid (CSF) is produced constantly and diffuses out of the medulla into the cerebrospinal room,  $Na_2S$  is diluted and may chemically react with substances in the CSF before it can diffuse inside the medulla.

# Neuronal Interaction between Na<sub>2</sub>S and DEA-NONOate

The stimulating effect of DEA-NONOate was inhibited by blocking  $H_2S$  synthesis with oxamic acid in 75% of the units and, *vice versa*, blocking NO synthesis by L-NAME reduced the neuronal activity after Na<sub>2</sub>S administration compared with the activity after Na<sub>2</sub>S alone. This indicates a cooperative effect of NO and  $H_2S$ , which does obviously control the activity of most but not all spinal trigeminal neurons. Olcegepant following L-NAME did not lead to a further decrease in neuronal activity, suggesting that the signaling pathway of NO/H<sub>2</sub>S is upstream of central CGRP release in the STN. CGRP has previously been demonstrated to be involved in the nociceptive transmission of signals to second order neurons (42, 43).

### Systemic Administration of DEA-NONOate

The increased neuronal activity caused by DEA-NONOate is in line with the previously described stimulating effect of "NO donors," glycerol trinitrate (GNT, nitroglycerin), and sodium nitroprusside, on trigeminal neurons (44, 45) and is on principle consistent with the effect of these substances in triggering headache attacks in patients suffering from migraine (46). However, the stimulating effect of DEA-NONOate appears to be transient, whereas GTN caused a biphasic activation of spinal trigeminal neurons with an acute and a delayed increase in activity starting roughly 1 h after infusion after (44).

The delayed effect of NO on central trigeminal activity may be associated with the expression or availability of CGRP and NO synthase in the trigeminal ganglion or ophthalmic region (47). Thus, NO may have different effects with differing timecourse, i.e., an acute effect already occurring during infusion followed by a subacute effect of increased neuronal activity within the next 20 min and a late effect appearing as upregulation of proteins like CGRP, CGRP receptors, and NO synthase some hours after infusion of NO donors (47, 48). Similar changes in the human trigeminal system may eventually trigger headache attacks in migraineurs several hours after i.v. infusion of GTN (49).

# Systemic Administration of Na<sub>2</sub>S Combined with DEA-NONOate

Diethylamine-NONOate applied 20 min after Na<sub>2</sub>S infusion did not lead to a significant increase in neuronal activity. Conversely, the activity after Na<sub>2</sub>S infusion following 20 min after DEA-NONOate increased rapidly, before it decreased again.

As discussed above, endogenous NO and  $H_2S$  are known to form HNO, which is an effective TRPA1 receptor agonist. HNO stimulates TRPA1 expressing peptidergic sensory neurons to release CGRP and other neuropeptides. Recent experiments in our group have shown that combined stimulation of trigeminal tissues with Na<sub>2</sub>S and NO donors cause CGRP release on all levels of the trigeminal system acting synergistically compared to stimulation with either these substances alone (28). In these preparations,  $H_2S$  appeared to be the rate-limiting factor for HNO formation. This synergistic action of  $H_2S$  and NO was examined in an *in vivo* situation in the present experiments.

Looking closer to the time-course of activation after systemic Na<sub>2</sub>S infusion, the neuronal activity increased particularly during the second 10-min period after Na<sub>2</sub>S administration, whereas after Na<sub>2</sub>S following DEA-NONOate, it increased already during the first 10-min period in the whole sample of units. This may indicate a synergistic action of H<sub>2</sub>S and NO leading to an accelerated activation and supports the hypothesis of an interaction between the two substances with subsequent activation of neurons, most likely by HNO formation. Conversely, DEA-NONOate administered after Na<sub>2</sub>S did not increase the effect of Na<sub>2</sub>S. This difference may be due to the rate-limiting character of Na<sub>2</sub>S, i.e., in the presence of Na<sub>2</sub>S there is sufficient production of NO but not vice versa. Thus, infusion of DEA-NONOate after Na<sub>2</sub>S did not lead to a further increase in activity, since the reaction partner H<sub>2</sub>S was missing. In contrast, additional Na<sub>2</sub>S could increase the NO effect and accelerate its stimulating action on trigeminal neurons.

The individual experiments varied again into two directions with stimulated (two-third) and inhibited units (one-third). This is not surprising in the light of the discussion about the  $Na_2S$  effects above.

# Inhibition of Endogenous H<sub>2</sub>S and NO Synthesis

To further analyze the cooperative effect of endogenous NO and  $H_2S$ , we inhibited the enzymes responsible for the synthesis of the reaction partners. We used oxamic acid as an inhibitor of the  $H_2S$  generating CBS (50) and examined the neuronal activity stimulated by DEA-NONOate. Conversely, in another group of experiments, L-NAME was used to explore if the suppression of endogenous NO synthesis has an effect on the Na<sub>2</sub>S-stimulated neuronal activity.

### Systemic Administration of Oxamic Acid following DEA-NONOate

Infusion of oxamic acid inhibited the majority of units activated by administration of DEA-NONOate in the present study. This provides further evidence for the interaction of NO and  $H_2S$ , which has previously been recognized in other experiments of our group, where the meningeal blood flow increase evoked by systemic application of DEA-NONOate was reduced after topically applied oxamic acid (21). On the other hand, the result may indicate that endogenous  $H_2S$  can also be formed non-enzymatically, even if this may play a minor role [reviewed in Ref. (51)]. Another possibility is that not all neurons are controlled or are even inhibited by the HNO pathway, as discussed above.

### L-NAME following Systemic Administration of Na<sub>2</sub>S

An inhibitory effect on the ongoing spinal trigeminal activity by the unspecific NOS inhibitor L-NAME was presented previously (29). We applied L-NAME 20 min after i.v. infusion of Na<sub>2</sub>S to further probe the assumed interaction between H<sub>2</sub>S and NO in forming HNO. L-NAME caused a decrease in spontaneous neuronal activity compared to the activity after Na<sub>2</sub>S from minute 6 after the administration; around 20 min after L-NAME the activity fell even below baseline activity. This supports our notion that the activating effect of H<sub>2</sub>S on the majority of spinal trigeminal neurons depends on the presence of NO.

Calcitonin gene-related peptide has been identified as a predominantly pro-nociceptive neuromodulator by iontophoretic application of CGRP and CGRP receptor antagonists close to the recorded neurons in the trigemino-cervical brainstem complex (42). Following L-NAME administration we eventually applied a CGRP receptor inhibitor, Olcegepant (BIBN4096BS), with proven therapeutic efficiency in acute migraine headache (52). This did not lead to a further decrease in neuronal activity, fitting the hypothesis that CGRP is released by TRPA1 activation upon HNO formed by NO and H<sub>2</sub>S. When NO production was

# REFERENCES

- Jiang J, Chan A, Ali S, Saha A, Haushalter KJ, Lam W-LM, et al. Hydrogen sulfide – mechanisms of toxicity and development of an antidote. *Sci Rep* (2016) 6:20831. doi:10.1038/srep20831
- Kimura H. Hydrogen sulfide as a neuromodulator. Mol Neurobiol (2002) 26(1):13–9. doi:10.1385/MN:26:1:013
- Tang C, Li X, Du J. Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system. *Curr Vasc Pharmacol* (2006) 4(1):17–22. doi:10.2174/157016106775203144

interrupted by L-NAME, HNO formation and hence CGRP release was presumably reduced in the STN with the consequence of decreased neuronal activity, as demonstrated earlier (29).

# CONCLUSION

Spinal trigeminal neurons may be activated or inhibited by H<sub>2</sub>S-NO-CGRP signaling. Although direct actions of H<sub>2</sub>S and NO cannot be excluded, we collected strong evidence for a cooperative effect of H<sub>2</sub>S and NO forming HNO, which upon TRPA1 activation modulates CGRP release and the activity of these neurons. Endogenous NO production may contribute more to the maintenance of spinal trigeminal activity than endogenous H<sub>2</sub>S production, while the latter may be the rate-limiting factor. Our in vivo experiments point to divergent responses to H<sub>2</sub>S of neurons in the trigeminal system. We suggest similar divergent effects of this neuromodulator when it is endogenously produced in the human body. Depending on its blood concentration and the interaction with other modulators like NO, it may be an important factor for the generation of migraine pain and tensiontype headaches. Progress in understanding the role of H<sub>2</sub>S in trigeminal nociception may support further pharmacological studies of the H<sub>2</sub>S-NO-CGRP system aiming at new options in the therapy of primary headaches.

# **ETHICS STATEMENT**

The experiments were approved by the District Government of Unterfranken, Bavaria.

# **AUTHOR CONTRIBUTIONS**

CT performed the experiments, analyzed the data, and wrote the manuscript. RC instructed the experimental work and data analysis and contributed to the manuscript. KM designed and supervised the experiments and wrote the manuscript.

# ACKNOWLEDGMENTS

We like to thank Jana Schramm and Birgit Vogler for excellent technical assistance and Prof. Milos Filipovic for providing Na<sub>2</sub>S.

# **FUNDING**

The study received support from the Emerging Fields Initiative (EFI) of the University Erlangen-Nürnberg and the FP7 program EUROHEADPAIN (grant agreement no: 602633) of the European Union.

- Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem J* (1982) 206(2):267–77. doi:10.1042/bj2060267
- Griffith OW. Mammalian sulfur amino acid metabolism: an overview. Methods in Enzymology, Herausgeber (Sulfur and Sulfur Amino Acids; Bd. 143) Academic Press (1987). p. 366–76. Available from: http://www. sciencedirect.com/science/article/pii/0076687987430656
- 6. Erickson PF, Maxwell IH, Su LJ, Baumann M, Glode LM. Sequence of cDNA for rat cystathionine gamma-lyase and comparison of deduced amino acid

sequence with related *Escherichia coli* enzymes. *Biochem J* (1990) 269(2): 335–40. doi:10.1042/bj2690335

- Swaroop M, Bradley K, Ohura T, Tahara T, Roper MD, Rosenberg LE, et al. Rat cystathionine beta-synthase. Gene organization and alternative splicing. *J Biol Chem* (1992) 267(16):11455–61.
- 8. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* (1996) 16(3):1066–71.
- 9. Yang W, Yang G, Jia X, Wu L, Wang R. Activation of KATP channels by H2S in rat insulin-secreting cells and the underlying mechanisms. *J Physiol* (2005) 569(Pt 2):519–31. doi:10.1113/jphysiol.2005.097642
- Xiao L, Wu YM, Zhang H, Liu YX, He RR. Hydrogen sulfide facilitates carotid sinus baroreflex in anesthetized rats. *Acta Pharmacol Sin* (2006) 27(3):294–8. doi:10.1111/j.1745-7254.2006.00269.x
- Fitzgerald R, DeSantiago B, Lee DY, Yang G, Kim JY, Foster DB, et al. H2S relaxes isolated human airway smooth muscle cells via the sarcolemmal KATP channel. *Biochem Biophys Res Commun* (2014) 446(1):393–8. doi:10.1016/j. bbrc.2014.02.129
- Althaus M, Urness K, Clauss W, Baines D, Fronius M. The gasotransmitter hydrogen sulphide decreases Na+ transport across pulmonary epithelial cells. *Br J Pharmacol* (2012) 166(6):1946–63. doi:10.1111/j.1476-5381.2012.01909.x
- Módis K, Bos EM, Calzia E, van Goor H, Coletta C, Papapetropoulos A, et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects. *Br J Pharmacol* (2014) 171(8):2123–46. doi:10.1111/bph.12368
- Kamoun P. H2S, a new neuromodulator. Med Sci (Paris) (2004) 20(6–7):697– 700. doi:10.1051/medsci/2004206-7697
- Eberhardt M, Dux M, Namer B, Miljkovic J, Cordasic N, Will C, et al. H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. *Nat Commun* (2014) 5:4381. doi:10.1038/ncomms5381
- Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Högestätt ED, et al. Pungent products from garlic activate the sensory ion channel TRPA1. Proc Natl Acad Sci U S A (2005) 102(34):12248–52. doi:10.1073/ pnas.0505356102
- Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. *Cell* (2003) 112(6):819–29. doi:10.1016/S0092-8674(03)00158-2
- Huang D, Li S, Dhaka A, Story GM, Cao Y-Q. Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. *Mol Pain* (2012) 8:66. doi:10.1186/1744-8069-8-66
- Eberhardt MJ, Filipovic MR, Leffler A, de la Roche J, Kistner K, Fischer MJ, et al. Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1) a possible mechanism of metabolic neuropathies. *J Biol Chem* (2012) 287(34):28291–306. doi:10.1074/jbc.M111.328674
- Zygmunt PM, Högestätt ED. TRPA1. Handb Exp Pharmacol (2014) 222: 583–630. doi:10.1007/978-3-642-54215-2\_23
- Dux M, Will C, Vogler B, Filipovic MR, Messlinger K. Meningeal blood flow is controlled by H2 S-NO crosstalk activating a HNO-TRPA1-CGRP signalling pathway. Br J Pharmacol (2016) 173(3):431–45. doi:10.1111/bph.13164
- Schepelmann K, Ebersberger A, Pawlak M, Oppmann M, Messlinger K. Response properties of trigeminal brain stem neurons with input from dura mater encephali in the rat. *Neuroscience* (1999) 90(2):543–54. doi:10.1016/ S0306-4522(98)00423-0
- Bove GM, Moskowitz MA. Primary afferent neurons innervating guinea pig dura. J Neurophysiol (1997) 77(1):299–308.
- Nassini R, Materazzi S, Vriens J, Prenen J, Benemei S, De Siena G, et al. The "headache tree" via umbellulone and TRPA1 activates the trigeminovascular system. *Brain J Neurol* (2012) 135(Pt 2):376–90. doi:10.1093/brain/ awr272
- Filipovic MR, Eberhardt M, Prokopovic V, Mijuskovic A, Orescanin-Dusic Z, Reeh P, et al. Beyond H2S and NO interplay: hydrogen sulfide and nitroprusside react directly to give nitroxyl (HNO). A new pharmacological source of HNO. J Med Chem (2013) 56(4):1499–508. doi:10.1021/jm3012036
- Filipovic MR, Miljkovic JL, Nauser T, Royzen M, Klos K, Shubina T, et al. Chemical characterization of the smallest S-nitrosothiol, HSNO; cellular cross-talk of H2S and S-nitrosothiols. *J Am Chem Soc* (2012) 134(29): 12016–27. doi:10.1021/ja3009693

- Andersson DA, Gentry C, Bevan S. TRPA1 has a key role in the somatic pro-nociceptive actions of hydrogen sulfide. *PLoS One* (2012) 7(10):e46917. doi:10.1371/journal.pone.0046917
- Wild V, Messlinger K, Fischer MJM. Hydrogen sulfide determines HNOinduced stimulation of trigeminal afferents. *Neurosci Lett* (2015) 602:104–9. doi:10.1016/j.neulet.2015.06.056
- De Col R, Koulchitsky SV, Messlinger KB. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. *Neuroreport* (2003) 14(2):229–32. doi:10.1097/00001756-200302100-00014
- Miyamoto R, Otsuguro K, Ito S. Time- and concentration-dependent activation of TRPA1 by hydrogen sulfide in rat DRG neurons. *Neurosci Lett* (2011) 499(2):137–42. doi:10.1016/j.neulet.2011.05.057
- Stucky CL, Dubin AE, Jeske NA, Malin SA, McKemy DD, Story GM. Roles of transient receptor potential channels in pain. *Brain Res Rev* (2009) 60(1):2–23. doi:10.1016/j.brainresrev.2008.12.018
- Barabas ME, Kossyreva EA, Stucky CL. TRPA1 is functionally expressed primarily by IB4-binding, non-peptidergic mouse and rat sensory neurons. *PLoS ONE* (2012) 7(10):e47988. doi:10.1371/journal.pone.0047988
- Smith HS. Hydrogen sulfide's involvement in modulating nociception. *Pain Physician* (2009) 12(5):901–10.
- Kuksis M, Ferguson AV. Actions of a hydrogen sulfide donor (NaHS) on transient sodium, persistent sodium, and voltage-gated calcium currents in neurons of the subfornical organ. J Neurophysiol (2015) 114(3):1641–51. doi:10.1152/jn.00252.2015
- Kolluru GK, Shen X, Bir SC, Kevil CG. Hydrogen sulfide chemical biology: pathophysiological roles and detection. *Nitric Oxide Biol Chem* (2013) 35:5–20. doi:10.1016/j.niox.2013.07.002
- Nielsen AH, Vollertsen J, Hvitved-Jacobsen T. Kinetics and stoichiometry of aerobic sulfide oxidation in wastewater from sewers-effects of pH and temperature. *Water Environ Res* (2006) 78(3):275–83.
- Olson KR, Dombkowski RA, Russell MJ, Doellman MM, Head SK, Whitfield NL, et al. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* (2006) 209(Pt 20):4011–23. doi:10.1242/jeb.02480
- Yoo D, Jupiter RC, Pankey EA, Reddy VG, Edward JA, Swan KW, et al. Analysis of cardiovascular responses to the H<sub>2</sub>S donors Na<sub>2</sub>S and NaHS in the rat. Am J Physiol Heart Circ Physiol (2015) 309(4):H605–14. doi:10.1152/ ajpheart.00171.2015
- Heine CL, Schmidt R, Geckl K, Schrammel A, Gesslbauer B, Schmidt K, et al. Selective irreversible inhibition of neuronal and inducible nitric-oxide synthase in the combined presence of hydrogen sulfide and nitric oxide. *J Biol Chem* (2015) 290(41):24932–44. doi:10.1074/jbc.M115.660316
- Denner AC, Vogler B, Messlinger K, De Col R. Role of transient receptor potential ankyrin 1 receptors in rodent models of meningeal nociception – experiments in vitro. *Eur J Pain* (2016) 21:843–54. doi:10.1002/ejp.986
- Nöbel M, Feistel S, Ellrich J, Messlinger K. ATP-sensitive muscle afferents activate spinal trigeminal neurons with meningeal afferent input in rat – pathophysiological implications for tension-type headache. J Headache Pain (2016) 17(1):75. doi:10.1186/s10194-016-0668-z
- Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol (2004) 142(7):1171–81. doi:10.1038/sj.bjp.0705807
- Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. *J Neurosci* (2005) 25(25):5877–83. doi:10.1523/JNEUROSCI.0869-05.2005
- Koulchitsky S, Fischer MJM, De Col R, Schlechtweg PM, Messlinger K. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat – possible implications for the pathophysiology of headaches. *J Neurophysiol* (2004) 92(3):1320–8. doi:10.1152/jn.01210.2003
- Koulchitsky S, Fischer MJM, Messlinger K. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. *Cephalalgia* (2009) 29(4):408–17. doi:10.1111/j.1468-2982.2008.01745.x
- Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. *Cephalalgia* (1999) 19(7):660–7. doi:10.1046/j.1468-2982.1999. 019007660.x

- Dieterle A, Fischer MJM, Link AS, Neuhuber WL, Messlinger K. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. *Cephalalgia* (2011) 31(1):31–42. doi:10.1177/0333102410375725
- Seiler K, Nusser JI, Lennerz JK, Neuhuber WL, Messlinger K. Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment. *J Headache Pain* (2013) 14:74. doi:10.1186/1129-2377-14-74
- Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. *Neuroreport* (1993) 4(8):1027–30. doi:10.1097/00001756-199308000-00008
- 50. Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, Cirino G, et al. Selectivity of commonly used pharmacological inhibitors for cystathionine  $\beta$  synthase (CBS) and cystathionine  $\gamma$  lyase (CSE). *Br J Pharmacol* (2013) 169(4):922–32. doi:10.1111/bph.12171
- Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? *FASEB J* (2002) 16(13):1792–8. doi:10.1096/fj.02-0211hyp

 Rudolf K, Eberlein W, Engel W, Pieper H, Entzeroth M, Hallermayer G, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N<sup>2</sup>-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. *J Med Chem* (2005) 48(19):5921–31. doi:10.1021/jm0490641

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Teicher, De Col and Messlinger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.